(MENAFN- Investor Ideas)
-->
Cannabis / Pharma Stock News: Optimind Pharma Commences Trading on The CSE Under Ticker Symbol (CSE: OMND)
Toronto, Ontario - August 4, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Optimind Pharma Corp. (CSE: OMND) ('Optimind' or the 'Company') today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol 'OMND'.
Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety profile, which remains the primary business of the clinic.
Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.
Optimind is also a 40% shareholder of Manitari Pharma. Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer's Licence for Psilocybin Research Purposes.
'The public listing of Optimind represents a significant milestone in the growth of our company. It's an important step that will help facilitate our mission to provide psychedelic-assisted therapies for the public and improve their quality of life,' commented Tomas Sipos, Chief Executive Officer at Optimind.
'Optimind is on it's way to becoming a leader in psychedelic-assisted therapy that will provide patients throughout North America with choices that promote mental, physical, and spiritual wellness. I'm supportive and enthusiastic to be a part of this exciting development and opportunity,' commented The Hon. Tony Clement, Chair of the Advisory Board at Optimind.
'Manitari Pharma's vision is to incorporate cutting-edge science with experience from shamanic traditions to create wellness psilocybin products used to treat mental illness and create spiritual well-being. As an Indigenous group out of Kanesatake Quebec, we are delighted our partners at Optimind are now trading on the CSE. This is vital in expanding our mission in ensuring the future mental health of First Nations and the global community at large,' said Anna Freeman, Chief Executive Officer of Manitari Pharma.
'Psychedelic-assisted therapy has the power to drastically transform people's lives around the world. At Optimind, our mission is to help people live life fully again through our treatment,' commented Dr. Michael Hart, Chief Operating Officer at Optimind.
About Optimind
Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments. Optimind prides itself on providing quality education and health care to patients. Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety profile, which remains the primary business of the clinic.
Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities. For more information, visit .
For more information, please contact:
Tomas Sipos
Chief Executive Officer
Caution regarding Forward-Looking Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons', as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: Learn more about publishing your news release and our other news services on the Investorideas.com newswire and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories for Cannabis stocks and Psychedelic Stocks
Buy a cannabis guest post on Investorideas.com About Investorideas.com
Sign up for free stock news alerts at Investorideas.com
MENAFN04082022000142011025ID1104648535
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.